These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 10759015)

  • 1. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
    Goldsmith JC
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoaffinity purification of factor VIII.
    Weinstein RE
    Ann Clin Lab Sci; 1989; 19(2):84-91. PubMed ID: 2502062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral safety of a new highly purified factor VIII (OCTATE).
    Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
    J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
    Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
    J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
    Smith KJ; Lusher JM; Cohen AR; Salzman P
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and viral safety validation study of a pasteurized therapeutic concentrate of antithrombin III obtained through affinity chromatography.
    Biescas H; Gensana M; Fernández J; Ristol P; Massot M; Watson E; Vericat F
    Haematologica; 1998 Apr; 83(4):305-11. PubMed ID: 9592979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates.
    Hilfenhaus J; Weidmann E
    Arzneimittelforschung; 1986 Apr; 36(4):621-5. PubMed ID: 3013213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
    Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
    Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates.
    Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM
    Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Affinity chromatography to remove viruses during preparation of plasma derivatives.
    Lawrence JE
    Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate.
    Hilfenhaus J; Nowak T
    Vox Sang; 1994; 67 Suppl 1():62-6. PubMed ID: 8091740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human parvovirus PARV4 in clotting factor VIII concentrates.
    Fryer JF; Hubbard AR; Baylis SA
    Vox Sang; 2007 Nov; 93(4):341-7. PubMed ID: 18070279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogen safety of Beriate®.
    Gröner A
    Thromb Res; 2014 Nov; 134 Suppl 1():S10-5. PubMed ID: 24726555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of hepatitis A antibody over a process for the preparation of a high-purity factor VIII concentrate.
    Hart H; Jones A; Cubie H; McIntosh RV; Cuthbertson B
    Vox Sang; 1994; 67 Suppl 1():51-5. PubMed ID: 8091738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
    Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
    Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
    Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY
    Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.